| Symbol | AIXC |
|---|---|
| Name | QUALIGEN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2042 CORTE DEL NOGAL,SUITE B, CARLSBAD, California, 92011, United States |
| Telephone | +1 760 918-9165 |
| Fax | — |
| — | |
| Website | https://www.qlgntx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001460702 |
| Description | Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. Additional info from NASDAQ: |
(99% Neutral) QUALIGEN THERAPEUTICS, INC. (AIXC) Announces Business Combination
Read moreNew Form 3 - AIxCrypto Holdings, Inc. <b>Filed:</b> 2026-06-12 <b>AccNo:</b> 0001493152-26-028576 <b>Size:</b> 3 KB
Read more(70% Positive) QUALIGEN THERAPEUTICS, INC. (AIXC) Announces Business Combination
Read moreAIxCrypto Announces First Quarter 2026 Earnings Release Date and Conference Call Details
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Agentir Progress, Chutes AI Collaboration Framework, and Bitcoin 2026 Engagement
Read moreNew Form S-8 - AIxCrypto Holdings, Inc. <b>Filed:</b> 2026-04-17 <b>AccNo:</b> 0001493152-26-017872 <b>Size:</b> 404 KB
Read more(99% Neutral) QUALIGEN THERAPEUTICS, INC. (AIXC) Announces Business Combination
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: RWA Exploration, Ecosystem Development, and External Engagement
Read moreAIxCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: AI Agent Development and Internal Testing Progress
Read moreAIxCrypto Highlights Full Year 2025 Transformation and Next Phase of Growth
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06086522 | Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced … | Phase1 | Solid Tumor | Recruiting | 2023-11-01 | 2026-12-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| QN-302 | Other | Phase PHASE1 | Solid Tumor | RECRUITING | NCT06086522 |